MedTrace Logo

Oral Health in Breast Cancer Survivors on Aromatase Inhibitors

NCT01693731 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2015-05-20

No results posted yet for this study

Summary

The purpose of this study is to determine how aromatase inhibitors (AIs) such as Arimidex, Aromasin or Femara affect a woman's oral health and oral health related quality of life. Patients, dental professionals and medical oncologists will benefit from a greater understanding of the best oral care follow up practices of breast cancer survivors using aromatase inhibitors.

Conditions

  • Periodontal Disease
  • Quality of Life

Sponsors & Collaborators

  • National Institute of Dental and Craniofacial Research (NIDCR)

    collaborator NIH

  • University of Michigan

    lead OTHER

Principal Investigators

  • L. Susan Taichman, RDH MPH PhD · University of Michigan

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01693731 on ClinicalTrials.gov